-
Mashup Score: 19PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik - 18 day(s) ago
Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik - 1 month(s) ago
Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
#PRIMORDIUM trial evaluates apalutamide + ADT for high-risk biochemical recurrence of #ProstateCancer after prostatectomy. @ProfHadaschik and @CaPsurvivorship discuss the integration of PET imaging not just at baseline but as a primary endpoint > https://t.co/lZWI93AF1l https://t.co/CqWBty3xuR